CA3236482A1 - Alginates modifies et procedes de fabrication et d'utilisation associes - Google Patents

Alginates modifies et procedes de fabrication et d'utilisation associes Download PDF

Info

Publication number
CA3236482A1
CA3236482A1 CA3236482A CA3236482A CA3236482A1 CA 3236482 A1 CA3236482 A1 CA 3236482A1 CA 3236482 A CA3236482 A CA 3236482A CA 3236482 A CA3236482 A CA 3236482A CA 3236482 A1 CA3236482 A1 CA 3236482A1
Authority
CA
Canada
Prior art keywords
alginate
modified
group
substituted
azide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236482A
Other languages
English (en)
Inventor
Yevgeny Brudno
Christopher Moody
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of CA3236482A1 publication Critical patent/CA3236482A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La perte de capacités de réticulation dans des échafaudages d'alginates hautement substitués est un problème important affectant l'utilisation de polymères d'alginates dans des implants, l'administration de cellules et l'ingénierie tissulaire. Des échafaudages d'alginates modifiés qui conservent leurs propriétés de gélification sous une forte modification chimique sont divulgués, ainsi que des procédés de fabrication et d'utilisation associés.
CA3236482A 2021-10-28 2022-10-28 Alginates modifies et procedes de fabrication et d'utilisation associes Pending CA3236482A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163272975P 2021-10-28 2021-10-28
US63/272,975 2021-10-28
US202163288906P 2021-12-13 2021-12-13
US63/288,906 2021-12-13
PCT/US2022/078944 WO2023077112A1 (fr) 2021-10-28 2022-10-28 Alginates modifiés et procédés de fabrication et d'utilisation associés

Publications (1)

Publication Number Publication Date
CA3236482A1 true CA3236482A1 (fr) 2023-05-04

Family

ID=86158838

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236482A Pending CA3236482A1 (fr) 2021-10-28 2022-10-28 Alginates modifies et procedes de fabrication et d'utilisation associes

Country Status (2)

Country Link
CA (1) CA3236482A1 (fr)
WO (1) WO2023077112A1 (fr)

Also Published As

Publication number Publication date
WO2023077112A1 (fr) 2023-05-04

Similar Documents

Publication Publication Date Title
AU2019200810B2 (en) Modified alginates for anti-fibrotic materials and applications
Huang et al. Hydrogel scaffolds for differentiation of adipose-derived stem cells
US20200197526A1 (en) Refillable drug delivery devices and methods of use thereof
Kempe et al. In situ forming implants—an attractive formulation principle for parenteral depot formulations
ES2451651T3 (es) Composiciones de liberación inmediata para el tratamiento de daños tisulares
EP2455104B1 (fr) Hydrogels de PEG bio-fonctionnalisés et solubles dépendant à un stimulus
ES2708076T3 (es) Peptidoglicanos sintéticos que se unen al ácido hialurónico, preparación y métodos de uso
Huang et al. Marine-inspired molecular mimicry generates a drug-free, but immunogenic hydrogel adhesive protecting surgical anastomosis
CA2720203A1 (fr) Composition osteogenique comprenant un complexe facteur de croissance/polymere amphiphile un sel soluble de cation et un support organique
Liu et al. Release of O-GlcNAc transferase inhibitor promotes neuronal differentiation of neural stem cells in 3D bioprinted supramolecular hydrogel scaffold for spinal cord injury repair
WO2016189088A1 (fr) Composition pour le traitement des lesions tissulaires
Liu et al. Development of a thermosensitive hydrogel loaded with DTT and SDF-1 facilitating in situ periodontal bone regeneration
EP4088757A1 (fr) Hydrogel de sulfate de chondroïtine fonctionnalisé par un dérivé de phénol et son utilisation
Mehta et al. Sustained intra-cartilage delivery of interleukin-1 receptor antagonist using cationic peptide and protein-based carriers
JP2009523791A (ja) １．０〜１００ｋＤａの分子量を有するデキストランを含む薬剤及びその調製方法
Moody et al. Restoring carboxylates on highly modified alginates improves gelation, tissue retention and systemic capture
CA3236482A1 (fr) Alginates modifies et procedes de fabrication et d'utilisation associes
EP3153155B1 (fr) Dispositifs rechargeables d'administration de médicaments et leurs procédés d'utilisation
US20210353767A1 (en) Compositions and methods for drug delivery
KR20220131197A (ko) 조직 공학용 자발 호흡성 바이오소재
US20230390403A1 (en) Compositions and methods for drug delivery
US20220401562A1 (en) Refillable drug delivery devices and methods of use thereof
ES2874930T3 (es) Dispositivos recargables de administración de fármacos y procedimientos de uso de los mismos
Noverraz Development of functionalized alginate-based hydrogels to reduce fibrosis in the transplantation of microencapsulated cells
Holmes Development of Biomimetic Hydrogels as Cell-Laden Devices for Muscle Regeneration